Photo illustration: Axios Visuals. Photo: Courtesy of LongeVC
LongeVC is raising $120 million for its second fund to invest in early and mid-stage biotech and "longevity-focused" startups.
Why it matters: In what some have called the most difficult fundraising environment in years, LongeVC managing partner Sergey Jakimov sees major early-stage investment opportunities.
